Kookjeon Pharmaceutical Co., Ltd. (KOSDAQ:307750)
South Korea · Delayed Price · Currency is KRW 2,345.00
+45.00 (1.96%)
At close: Sep 18, 2026
Kookjeon Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 126,598 | 168,844 | 172,478 | 306,192 | 324,839 | 537,308 | |
Market Cap Growth | -37.29% | -2.11% | -43.67% | -5.74% | -39.54% | - |
Enterprise Value | 135,336 | 189,611 | 178,557 | 319,290 | 284,635 | - |
Last Close Price | 2345.00 | 3365.00 | 3515.00 | 6222.17 | 6590.26 | 10900.81 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 99.34 | 63.47 | 36.30 | 133.06 |
PS Ratio | 0.94 | 1.29 | 1.26 | 2.51 | 3.13 | 6.30 |
PB Ratio | 1.11 | 1.76 | 1.77 | 3.14 | 3.52 | 6.46 |
P/TBV Ratio | 1.14 | 1.78 | 1.80 | 3.22 | 3.60 | 6.50 |
P/FCF Ratio | 11.85 | 22.53 | 82.14 | - | - | - |
P/OCF Ratio | 9.21 | 15.92 | 17.31 | - | - | 176.63 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.01 | 1.45 | 1.31 | 2.62 | 2.75 | - |
EV/EBITDA Ratio | 17.70 | 71.19 | 32.63 | 33.11 | 57.72 | - |
EV/EBIT Ratio | 57.64 | - | 486.92 | 49.05 | 81.60 | - |
EV/FCF Ratio | 12.66 | 25.30 | 85.04 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.36 | 0.48 | 0.67 | 0.81 | 0.64 | 0.09 |
Debt / EBITDA Ratio | 5.37 | 17.23 | 11.94 | 8.17 | 12.03 | 1.09 |
Debt / FCF Ratio | 3.80 | 6.13 | 31.11 | - | - | - |
Net Debt / Equity Ratio | 0.07 | 0.16 | 0.19 | 0.14 | -0.39 | -0.38 |
Net Debt / EBITDA Ratio | 0.99 | 5.77 | 3.38 | 1.45 | -7.22 | -4.35 |
Net Debt / FCF Ratio | 0.70 | 2.05 | 8.81 | -0.31 | 1.22 | 4.26 |
Asset Turnover | 0.69 | 0.67 | 0.62 | 0.58 | 0.68 | - |
Inventory Turnover | 4.81 | 5.02 | 4.22 | 4.05 | 4.62 | - |
Quick Ratio | 1.08 | 0.82 | 0.85 | 0.94 | 1.67 | 2.72 |
Current Ratio | 1.47 | 1.13 | 1.19 | 1.24 | 2.02 | 3.52 |
Return on Equity (ROE) | -1.94% | -4.98% | 0.55% | 4.95% | 10.12% | - |
Return on Assets (ROA) | 0.73% | -0.82% | 0.10% | 1.93% | 1.44% | - |
Return on Invested Capital (ROIC) | 1.90% | -2.26% | 0.20% | 7.75% | 5.15% | 9.38% |
Return on Capital Employed (ROCE) | 1.70% | -2.30% | 0.30% | 5.20% | 2.80% | 7.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -1.46% | -2.55% | 1.01% | 1.58% | 2.76% | 0.75% |
FCF Yield | 8.44% | 4.44% | 1.22% | -14.46% | -9.02% | -1.37% |
Payout Ratio | - | - | 28.26% | - | 5.48% | - |
Buyback Yield / Dilution | -2.37% | -0.51% | -1.09% | 4.23% | -16.16% | - |